In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms
- PMID: 15215148
- PMCID: PMC434201
- DOI: 10.1128/AAC.48.7.2771-2777.2004
In vitro and bactericidal activities of ABT-492, a novel fluoroquinolone, against Gram-positive and Gram-negative organisms
Abstract
In vitro activities of ABT-492, ciprofloxacin, levofloxacin, trovafloxacin, moxifloxacin, gatifloxacin, and gemifloxacin were compared. ABT-492 was more potent against quinolone-susceptible and -resistant gram-positive organisms, had activity similar to that of ciprofloxacin against certain members of the family Enterobacteriaceae, and had comparable activity against quinolone-susceptible, nonfermentative, gram-negative organisms. Bactericidal activity of ABT-492 was also evaluated.
Similar articles
-
In vitro activities of three nonfluorinated quinolones against representative bacterial isolates.Antimicrob Agents Chemother. 2001 Jun;45(6):1923-7. doi: 10.1128/AAC.45.6.1923-1927.2001. Antimicrob Agents Chemother. 2001. PMID: 11353655 Free PMC article.
-
In vitro activities of ME1036 (CP5609), a novel parenteral carbapenem, against methicillin-resistant staphylococci.Antimicrob Agents Chemother. 2004 Aug;48(8):2831-7. doi: 10.1128/AAC.48.8.2831-2837.2004. Antimicrob Agents Chemother. 2004. PMID: 15273088 Free PMC article.
-
In vitro activity of oral cephalosporin BAY v 3522 compared with other oral cephalosporins.Drugs Exp Clin Res. 1990;16(10):515-25. Drugs Exp Clin Res. 1990. PMID: 2100734
-
In vitro antibacterial activity and pharmacodynamics of new quinolones.Eur J Clin Microbiol Infect Dis. 2003 Apr;22(4):203-21. doi: 10.1007/s10096-003-0907-5. Epub 2003 Apr 1. Eur J Clin Microbiol Infect Dis. 2003. PMID: 12687416 Review.
-
Review of third-and fourth-generation fluoroquinolones in ophthalmology: in-vitro and in-vivo efficacy.Adv Ther. 2008 Oct;25(10):979-94. doi: 10.1007/s12325-008-0107-x. Adv Ther. 2008. PMID: 18836691 Review.
Cited by
-
Delafloxacin: A Review in Acute Bacterial Skin and Skin Structure Infections.Drugs. 2020 Aug;80(12):1247-1258. doi: 10.1007/s40265-020-01358-0. Drugs. 2020. PMID: 32666425 Free PMC article. Review.
-
Profile of a Novel Anionic Fluoroquinolone-Delafloxacin.Clin Infect Dis. 2019 Apr 8;68(Suppl 3):S213-S222. doi: 10.1093/cid/ciy1079. Clin Infect Dis. 2019. PMID: 30957164 Free PMC article. Review.
-
Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus.Antimicrob Agents Chemother. 2011 Feb;55(2):649-58. doi: 10.1128/AAC.01201-10. Epub 2010 Dec 6. Antimicrob Agents Chemother. 2011. PMID: 21135179 Free PMC article.
-
Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study.J Antimicrob Chemother. 2017 Dec 1;72(12):3471-3480. doi: 10.1093/jac/dkx329. J Antimicrob Chemother. 2017. PMID: 29029278 Free PMC article. Clinical Trial.
-
Delafloxacin, Finafloxacin, and Zabofloxacin: Novel Fluoroquinolones in the Antibiotic Pipeline.Antibiotics (Basel). 2021 Dec 8;10(12):1506. doi: 10.3390/antibiotics10121506. Antibiotics (Basel). 2021. PMID: 34943718 Free PMC article. Review.
References
-
- Almer, L. S., V. D. Shortridge, A. M. Nilius, J. M. Beyer, N. B. Soni, M. H. Bui, G. G. Stone, and R. K. Flamm. 2002. Antimicrobial susceptibility and molecular characterization of community-acquired methicillin-resistant Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 43:225-232. - PubMed
-
- Biedenbach, D. J., and R. N. Jones. 2000. Fluoroquinolone-resistant Haemophilus influenzae: frequency of occurrence and analysis of confirmed strains in the SENTRY Antimicrobial Surveillance Program (North and Latin America). Diagn. Microbiol. Infect. Dis. 36:255-259. - PubMed
-
- Blondeau, J. M., R. Laskowski, J. Bjarnason, and C. Stewart. 2000. Comparative in vitro activity of gatifloxacin, grepafloxacin, levofloxacin, moxifloxacin and trovafloxacin against 4,151 gram-negative and gram-positive organisms. Int. J. Antimicrob. Agents 14:45-50. - PubMed
-
- Dalhoff, A., and F. J. Schmitz. 2003. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur. J. Clin. Microbiol. Infect. Dis. 22:203-221. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources